Phase 3 RCT of 407 patients with AML or MDS having haploidentical PBSC transplant: day-100 grade 2-4 acute GVHD did not differ between low-dose ATG plus PTCy, standard ATG and PTCy (P = .210), and survival was similar; neutrophil and platelet recovery was faster with ATG/PTCy.
RCTn = 407
Yang et al. A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy